Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai
Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June in Dubai, United Arab Emirates. It was inaugurated by Prof. Dr. Frank Stangenberg-Haverkamp, Chairman of Merck Foundation Board of Trustees, and Senator, Dr. Rasha Kelej, CEO of Merck Foundation and President of Merck Foundation First Ladies Initiative along with The First Ladies of 14 African and Asian countries, who joined as the Guests of Honor and Keynote Speakers.
Senator Dr. Rasha Kelej, CEO of Merck Foundation and President of 'Merck Foundation First Ladies Initiative' emphasized, 'It is my great honor to welcome our esteemed Guests of Honor and Keynote Speakers, The First Ladies of Africa and Asia, and Ambassadors of our 'More Than a Mother' campaign to the 7th Edition of the Merck Foundation First Ladies Initiative – MFFLI Summit.
Through this important platform, we have collectively exchanged valuable experiences and engaged in meaningful discussions on the impact of our programs, which are aimed at transforming patient care and raising awareness of a wide range of critical social and health issues.'
Prof. Dr. Frank Stangenberg Haverkamp, Chairman of Merck Foundation Board of Trustees, added, 'At Merck Foundation, our goal is improving overall health and well-being by building healthcare capacity and by providing access to quality & equitable healthcare solutions in Africa, Asia and beyond. I would like to sincerely thank our Ambassadors and partners. Together, with your unwavering support and collaboration, we will continue to work towards our vision of a world where everyone can lead a healthy and happy life.'
The First Ladies of 14 countries, who are also the Ambassadors of 'Merck Foundation More Than a Mother', joined as Guests of Honor and Keynote Speakers. They are:
Senator, Dr. Rasha Kelej stated, 'I am proud to share that Merck Foundation has provided more than 2280 scholarships for young doctors from 52 countries in 44 critical and underserved specialties. Many of our Merck Foundation Alumni are becoming the first specialists in their countries. Together with our Ambassadors and Partners, we are making history and transforming the patient care landscape across Africa and beyond. Many of them are becoming the first specialists in their countries.'
'During our Conference, we also marked together the World Infertility Awareness Month, observed in June, through our signature campaign 'Merck Foundation More Than a Mother', which aims to empower infertile and childless women by providing access to information, education, and change of mindset. I am happy to share that out of the total 2280 scholarships, more than 700 scholarships have been provided for training in Fertility, Embryology, Sexual and Reproductive Medicine, Clinical Psychiatry, Women's Health, Urology, Laparoscopic Surgical Skills, and Family Medicine, to improve access to fertility care and women's health', she further added.
During the 7th Edition of Merck Foundation First Ladies Initiative -MFFLI Summit, two important occasions were marked: the 8th Anniversary of Merck Foundation and 13 years of Merck Foundation's development programs that started in 2012.
On the first day, the Plenary Session of the Merck Foundation First Ladies Initiative -MFFLI Summit took place, featuring a high-level panel discussion with the participating First Ladies of Africa and Asia. Moreover, a high-level ministerial panel discussion was held with African Ministers and top healthcare experts from across the globe.
On Day 2 of the conference, three key parallel sessions will be held: Two medical and scientific sessions covering Oncology and Fertility Topics, and a community awareness session, Merck Foundation Health Media Training. This session will emphasize the critical role of the media in influencing communities and driving cultural change, with regards to a wide range of social and health issues like Breaking Infertility Stigma, Supporting Girls' Education, Stopping GBV, Ending Child Marriage & FGM, Empowering Women, Diabetes and Hypertension Awareness.
The conference is being conducted in a hybrid format, enabling over 6,000 audiences from more than 70 countries to benefit, meet and discuss strategies and solutions for the health and social challenges in their countries safely and effectively.
Countries participating in the 7th Edition of Merck Foundation First Ladies Initiative:
Angola, Bangladesh, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Canada, Central Africa Republic, Cambodia, Chad, Côte d'Ivoire, Republic of the Congo, Democratic Republic of the Congo, Egypt, Ethiopia, France, Gabon, Germany, Ghana, Guinea – Bissau, Guinea – Conakry, India, Indonesia, Kenya, Lesotho, Liberia, Malawi, Malaysia, Maldives, Mali, Mauritania, Mauritius, Mexico, Mozambique, Myanmar, Namibia, Nepal, Niger, Nigeria, Peru, Philippines, Russia, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Sri Lanka, Sudan, Tanzania, Thailand, The Gambia, Togo, Tunisia, U.A.E, UK, Uganda, US, Vietnam, Zambia, Zimbabwe and more.
The 7th Edition of Merck Foundation First Ladies Initiative is streamed live on the social media handles of Merck Foundation and Senator, Dr. Rasha Kelej, CEO of Merck Foundation:
@Merck Foundation: Facebook, X, Instagram, and YouTube.
@Rasha Kelej: Facebook, X, Instagram, and YouTube.
Link to the Facebook live stream of Inaugural Session of Merck Foundation First Ladies High Level Panel: https://www.facebook.com/share/v/19CGzbGbZM/?mibextid=wwXIfr
Merck Foundation is transforming the Patient care landscape and making history together with their partners in Africa, Asia, and beyond, through:
Merck Foundation is also creating a culture shift and breaking the silence about a wide range of social and health issues in Africa and underserved communities through:
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
5 hours ago
- USA Today
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa. This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses. This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation. The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate's potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic. 'This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI's sponsorship, ReiThera's GRAd technology, the Ragon Institute's innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.' said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust. 'This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV,' said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI. The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions. 'We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality,' said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard. Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions. 'We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership,' said Stefano Colloca, CEO and co-Founder of ReiThera. 'This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions.' Principal Investigators Leading Clinical Trial Sites: Tariro Makadzange, Mutala Trust Theodorah Rirhandzu Ndzhukule, DTHF Limakatso Lebina, AHRI About IAVI IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at IAVI media contact Heather Teixeira hteixeira@ About Mutala Trust Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study. Mutala Trustmedia contact coms@ About ReiThera Srl. ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine. ReiThera media contact communication@ About the Ragon Institute of Mass General Brigham, MIT, and Harvard The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit Ragon Institutemedia contact ragoncommunications@ SOURCE: IAVI View the original press release on ACCESS Newswire
Miami Herald
14 hours ago
- Miami Herald
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa. This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses. This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation. The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate's potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic. "This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI's sponsorship, ReiThera's GRAd technology, the Ragon Institute's innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world." said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust. "This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV," said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI. The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions. "We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality," said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard. Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions. "We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership," said Stefano Colloca, CEO and co-Founder of ReiThera. "This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions." Principal Investigators Leading Clinical Trial Sites: Tariro Makadzange, Mutala TrustTheodorah Rirhandzu Ndzhukule, DTHFLimakatso Lebina, AHRI About IAVI IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at IAVI media contact Heather Teixeirahteixeira@ About Mutala Trust Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study. Mutala Trustmedia contact coms@ About ReiThera Srl. ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine. ReiThera media contact communication@ About the Ragon Institute of Mass General Brigham, MIT, and Harvard The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit Ragon Institutemedia contact ragoncommunications@ SOURCE: IAVI
Yahoo
15 hours ago
- Yahoo
New research reveals food choices that can boost immune system: 'Highlights the benefits of these traditional food products'
New research reveals food choices that can boost immune system: 'Highlights the benefits of these traditional food products' The health benefits of a Mediterranean diet have long been touted. New research suggests that an African heritage diet may offer similar advantages. Plant Based News summarized a study published in April in the journal Nature Medicine that indicated swapping Western foods for a traditional Northern Tanzanian diet — rich in green vegetables, legumes, fermented foods, and whole grains — could demonstrate positive impacts in a short time. Researchers assessed 23 men living in rural areas who typically adhered to a diet reflective of the Kilimanjaro region and who switched to a Western diet for a two-week period; 22 men living in urban areas who typically consumed a Western diet and switched to a traditional Kilimanjaro diet for the same period; and 22 men who typically followed a Western diet and added Mbege — a fermented banana and millet drink — for one week. These participants kept food diaries, and the research team took blood samples at the start of the study, two weeks in, and four weeks after it ended. The results indicated that switching to the traditional diet resulted in improved immune system function and "promoted the release of anti-inflammatory biomarkers, suggesting a potential reduction in [non-communicable disease] risk," according to a breakdown from News Medical. Meanwhile, switching to a Western diet "[upregulated] inflammatory biomarkers, resulting in chronic inflammation," and weakened immune responses. Those who added Mbege to their Western diet, however, saw metabolic and immune improvements relative to those who didn't. The trial adds to a growing body of research exploring the potential health benefits of plant-based diets. A 2022 study from Stanford University comparing identical twins, for example, found that plant-based diets were associated with lower insulin levels, reduced body weight, and lower levels of low-density lipoprotein cholesterol. A study from the National Institutes of Health suggested that obtaining the majority of dietary fats from plant sources, such as nuts, grains, and vegetables, could significantly lower heart disease-related mortality. Notably, plant-based diets can also provide a climate benefit. Cutting back on animal agriculture can lower the release of heat-trapping methane into the atmosphere and reduce the potential for water contamination. Meanwhile, investing in sustainable plant farming — including best practices for drought- and flood-resilience — can support biodiversity and soil health while strengthening global food systems that can be compromised by extreme weather. In a press release, corresponding author Quirijn de Mast noted, "Our study highlights the benefits of these traditional food products for inflammation and metabolic processes in the body. At the same time, we show how harmful an unhealthy Western diet can be." Why do you eat plant-based foods? The health benefits It's cheaper It's good for the planet I prefer the taste Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
